This resume summarizes the qualifications of Jane Yang, a scientist with extensive experience in cancer biology, transcriptional and epigenetic regulation, and cell differentiation. She has over 15 years of research experience, including positions at Genentech and Stanford University where she led projects discovering new mechanisms of action for small molecule inhibitors and identifying protein complexes involved in cell fate decisions. Her publications include high-impact articles in journals such as Cell Death and Differentiation and Genes & Development. She has strong skills in molecular and biochemical techniques and has received competitive NIH funding and honors for her work.
This document provides a summary of Jack Ryan Reifert's education, experience, publications, and research skills. Reifert holds a Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB and a B.S. in Pharmacological Chemistry from UCSD. He has postdoctoral and research experience studying mechanisms of amyloid beta induced neurodegeneration and ovarian cancer metastasis. Reifert has authored several publications investigating topics like tau fragmentation and the mechanism of action of cancer drug Bendamustine. His research skills include tissue culture, molecular techniques, microscopy, and cytotoxicity assays.
Jack Ryan Reifert has extensive experience in neuroscience research and industrial research. He received his Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB, focusing on amyloid beta induced neurodegeneration and the involvement of tau. He has held postdoctoral positions at UCSB studying bacterial peptide display to inhibit ovarian cancer metastasis and at UCSD investigating wnt/硫-catenin signaling in rheumatoid arthritis. Reifert has worked at several companies, contributing to FDA approval of Bendamustine and coordinating product releases. He is currently a postdoctoral fellow at UCSB studying targeted inhibition of proteases in ovarian cancer metastasis.
This document provides a summary of Swarnava Roy's background and qualifications. It outlines her extensive experience in molecular immunology, clinical research, and various laboratory techniques gained from her positions at research institutes including the National Institutes of Health and Cincinnati Children's Hospital Medical Center. It also lists her educational background, publications, awards, and teaching experience, demonstrating her expertise in areas of molecular biology, biochemistry, and immunology.
This document provides a summary of the research experience and qualifications of Jae-Mun Choi, a postdoctoral research associate at Baylor College of Medicine. It outlines his educational background, including a Ph.D. in structural biology from Baylor College of Medicine, as well as his extensive experience in structural biology research on viruses like norovirus and rotavirus. It also details his technical expertise and accomplishments, such as authoring several published research papers.
Lisa Salvador is a pharmaceutical research professional with over 10 years of industry experience focusing on clinical biomarkers, translational medicine, and drug development. She has a PhD in Cell Biology from Northwestern University and has held senior research roles at Bristol-Myers Squibb and GlaxoSmithKline. Her expertise includes cellular and molecular biology, gene therapy research, and diagnostic assay development. She has received numerous awards for her research contributions and leadership.
This curriculum vitae summarizes the educational and professional experience of Gang Zhang. It outlines his PhD in life sciences from Shandong Normal University in China and postdoctoral research at the University of Toronto. Zhang has over 15 years of experience in areas like genome editing, gene engineering, cellular and developmental biology, and reproduction biology. He has published over 20 papers as first author or co-author on related topics. The CV lists his supervision and research experience, awards, editorial roles, and invited speaking engagements at universities in Canada, US and China.
Xiumei Cao is a Chinese scientist currently working as an associate professor in Shanghai Jiaotong University. She has a Ph.D. in Biological Regulation from the Weizmann Institute of Science in Israel and extensive experience in immunology and cancer research. Her work has focused on the regulation of signaling pathways like TLR, TNF, and Sonic Hedgehog that are important in innate immunity and cancer. She has published numerous papers investigating the roles of various molecules in these pathways.
James J. Campbell has had an extensive career in immunology research. He is currently a Senior Director at ChemoCentryx, where he leads pre-clinical research teams investigating drug mechanisms of action. Previously, he was a Principal Investigator and Professor at Harvard Medical School, where he managed an immunology lab and published over 60 peer-reviewed papers. He has received many awards and honors for his research and expertise in T cell biology, chemokines, and skin and intestinal immunity.
This curriculum vitae summarizes the qualifications and experience of Ximiao He. He received his Ph.D. in Genomics from the Beijing Institute of Genomics in China, where he conducted research on genome databases and the analysis of human CpG islands and DNA methylation in cancer. He is currently a postdoctoral research fellow at the National Cancer Institute studying the effects of nucleosome occupancy and methylation on gene regulation. His research interests include DNA methylation, alternative splicing, and computational genomics tools. He has over 20 publications in peer-reviewed journals and has presented his research at several conferences.
Robert Pesich_PAVA_Stanford Resume v. 8_22_16Robert Pesich
油
Robert Pesich has extensive experience managing laboratory operations and research projects. He has overseen the daily activities of 25 researchers at Stanford University and the Palo Alto VA, including managing budgets, equipment, and regulatory compliance. Pesich has specialized skills in tissue sample processing, gene expression analysis, and bioinformatics. He has authored several publications characterizing gene expression profiles in normal and diseased tissues. Currently, Pesich also serves as President of a poetry non-profit organization.
Laura Ann Kelley is an experienced molecular and cell biologist currently working as an Associate Scientist at Eli Lilly & Company. She has over 10 years of experience in industry and academia employing techniques such as flow cytometry, high throughput screening assays, tissue/cell culture, molecular cloning, and more. Previously she has worked at Cedars-Sinai Medical Center, Amcyte Diabetes, and the University of California, San Diego conducting research in areas like antibody therapeutics, stem cells, and virology. She holds an M.S. in Biology from the University of Nevada, Las Vegas and has authored several publications and posters.
Molecular Biologist Academic CV for Industry or Private Sector Consideration Sirie Godshalk
油
Molecular Biologist with over thirteen years of hands-on research experience, impactful writer and presenter, dynamic leader and enthusiastic team player with an eye for great ideas and a passion to move science in new directions seeks challenging opportunities beyond the bench.
Jason C. Poole has 17 years of experience as a molecular biologist developing novel molecular and genetic assays. He has a PhD in molecular genetics and most recently worked at EMD Millipore developing qPCR and next generation sequencing assays that were commercialized. He is seeking a senior scientist or project leader position and has strong skills in areas like qPCR, sequencing, cloning, and assay development.
This document contains the curriculum vitae of Kun Yang. It summarizes his education, research experience, publications, conference presentations, honors and awards. Yang received a B.S. in Biotechnology from Beijing Normal University in 2006, and is currently pursuing a Ph.D. in Pathobiology at Brown University, with a focus on epigenetic regulation of bone development and osteoarthritis. His research has identified miR-365 and the Ihh signaling pathway as critical regulators of bone mineral density and osteoarthritis.
Alex Michael Ward is a virologist and cell biologist seeking a research position in biotech. He has 14 years of experience studying virus-host interactions and identifying therapeutic targets using genetic, proteomic, and cell-based approaches. He is a highly collaborative scientist who has independently managed a research team and obtained external funding. His work has resulted in numerous publications, presentations, and the development of novel assays.
Vani Hariharan has extensive experience in cellular biology, neurobiology, and developmental biology. She received her MS in Cellular Biology from the University of Georgia in 2013 and her BE in Biotechnology from Visvesvaraya Technological University in 2009. Her research has focused on studying Duchenne Muscular Dystrophy using zebrafish models and characterizing drug resistance in malaria parasites. She has worked as a research assistant at the University of Virginia and University of Georgia.
Kent E. Williams has extensive experience in neuroscience research. He holds an M.Sc. in Biology from Indiana State University and has completed coursework toward a Ph.D. in Neuroscience from Ohio State University. His research has focused on extracellular matrix proteins and their implications for angiogenesis and spinal cord injury. He has worked as an adjunct instructor and laboratory director and currently teaches at Vincennes University.
Kelvin Yaprianto is a biochemist from Indonesia who received his Bachelor of Science with Honours degree from the Walter and Eliza Hall Institute of Medical Research in Australia in 2013. He has extensive research experience investigating the roles of NF-虜B family transcription factors in promoting tumor cell survival and metastasis. Currently he works as a research assistant in stem cell and cancer research at PT. Kalbe Farma Tbk. in Jakarta.
Dhruv Patel is a research associate with expertise in molecular and cellular biology techniques including cloning, PCR, transfection and cell-based assays. He has work experience in pharmaceutical companies conducting discovery research to identify new drug targets. His education includes a M.S. in biological sciences and B.S. in pharmaceutical sciences. He is highly skilled in laboratory techniques and able to work independently or collaborate with others.
Genomics is the study of genomes through gene sequencing and comparisons within and across species. The Human Genome Project sequenced all human DNA. Technology allows study of genes and proteins through databases, microarrays, and proteomics. Genetic screening tests DNA to detect genetic disorders and cancer risk, while gene therapy aims to replace faulty genes as a treatment.
Assn. for molecular pathology vs. mtriad genetics case studyAltacit Global
油
This document summarizes a case study on the lawsuit between the Association for Molecular Pathology and Myriad Genetics regarding patents on the BRCA1 and BRCA2 genes. Myriad's scientists discovered the genes linked to breast cancer in 1994 and were granted patents. However, a lawsuit challenged the patents, arguing that genes cannot be patented. While a district court invalidated Myriad's patents, an appeals court upheld them. Ultimately, the US Supreme Court ruled that isolated DNA is not patentable subject matter, invalidating Myriad's patents.
Managing Health and Disease Using Omics and Big DataLaura Berry
油
Presented at the NGS Tech and Applications Congress: USA. To find out more, visit:
www.global-engage.com
Michael Snyder is a Professor, Chair of Genetics and Director of the Stanford Center for Genomics and Personalized Medicine at Stanford University. In this presentation Michael discusses using omics and big data to predict disease risk and catch early disease onset.
Geron's halted clinical trial using embryonic stem cell derivatives to treat spinal cord injury highlighted important lessons. Two key prerequisites for successful translation of pluripotent stem cell therapies are (1) reproducible growth and differentiation of stem cells in good manufacturing practice conditions to ensure a controlled cell source, and (2) extensive safety studies in animal models to determine adverse effects like teratoma formation and improve the treatment procedure. The intention to be first can disadvantage a trial by rushing critical development steps.
The document discusses the integration of diverse large-scale datasets to build comprehensive protein-protein interaction networks. It describes challenges with data from different sources having different identifiers, evidence types and quality. It also discusses methods used by STRING and other databases to combine data from curated databases, literature mining, primary datasets and transfer of interactions based on orthology. Examples are given of cell cycle studies in yeast that have analyzed periodically expressed genes and protein interactions.
This document provides a summary of Michael L. Avery's education and professional experience. He holds a BS and BGS in Cell Biology and Microbiology from the University of Kansas, and an MA in Microbiology. His experience includes over 13 years in analytical sciences and process development at Amgen, analytical chemistry research at Sigma-Aldrich Biosciences, and various roles supporting drug development and preclinical studies at 3M Pharmaceuticals and Quintiles. He has extensive experience in analytical techniques such as HPLC, CE, LC/MS, and related methods for characterizing proteins and small molecules.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
This curriculum vitae summarizes the educational and professional experience of Dr. Wen-Hai Chou. He received his PhD from the University of Texas Health Science Center in 2000 and is currently an Assistant Professor at Kent State University. His research focuses on the roles of Protein Kinase C and Lipocalin-2 in stroke. He has over 10 peer-reviewed publications in high impact journals such as the Journal of Neuroscience and Journal of Biological Chemistry.
This document provides a summary of Jack Ryan Reifert's education, experience, publications, and research skills. Reifert holds a Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB and a B.S. in Pharmacological Chemistry from UCSD. He has postdoctoral research experience at UCSB studying bacterial peptide display for ovarian cancer detection and inhibition. Reifert has over 10 years of experience in neuroscience research and industrial research, and he has authored several publications in peer-reviewed journals.
Sijin Wu has a Ph.D. in Biochemical Engineering and extensive experience in computational biology and computer-aided drug design. His research focuses on protein modeling, molecular dynamics simulation, and virtual screening. He has authored or co-authored over 15 publications and developed databases on proteins with targetable cysteines and cancer stem cell therapeutic targets. Wu seeks postdoctoral opportunities to further his work in these fields.
Jack Ryan Reifert is seeking a post-doctoral position in molecular mechanisms of age-related human diseases. He received his Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB, where his dissertation research investigated amyloid beta-induced neurodegeneration and the role of tau phosphorylation and cleavage. He has research experience in academia and industry, including publications, and is currently investigating tau fragmentation and amyloid beta signaling in neurodegeneration.
This curriculum vitae summarizes the qualifications and experience of Ximiao He. He received his Ph.D. in Genomics from the Beijing Institute of Genomics in China, where he conducted research on genome databases and the analysis of human CpG islands and DNA methylation in cancer. He is currently a postdoctoral research fellow at the National Cancer Institute studying the effects of nucleosome occupancy and methylation on gene regulation. His research interests include DNA methylation, alternative splicing, and computational genomics tools. He has over 20 publications in peer-reviewed journals and has presented his research at several conferences.
Robert Pesich_PAVA_Stanford Resume v. 8_22_16Robert Pesich
油
Robert Pesich has extensive experience managing laboratory operations and research projects. He has overseen the daily activities of 25 researchers at Stanford University and the Palo Alto VA, including managing budgets, equipment, and regulatory compliance. Pesich has specialized skills in tissue sample processing, gene expression analysis, and bioinformatics. He has authored several publications characterizing gene expression profiles in normal and diseased tissues. Currently, Pesich also serves as President of a poetry non-profit organization.
Laura Ann Kelley is an experienced molecular and cell biologist currently working as an Associate Scientist at Eli Lilly & Company. She has over 10 years of experience in industry and academia employing techniques such as flow cytometry, high throughput screening assays, tissue/cell culture, molecular cloning, and more. Previously she has worked at Cedars-Sinai Medical Center, Amcyte Diabetes, and the University of California, San Diego conducting research in areas like antibody therapeutics, stem cells, and virology. She holds an M.S. in Biology from the University of Nevada, Las Vegas and has authored several publications and posters.
Molecular Biologist Academic CV for Industry or Private Sector Consideration Sirie Godshalk
油
Molecular Biologist with over thirteen years of hands-on research experience, impactful writer and presenter, dynamic leader and enthusiastic team player with an eye for great ideas and a passion to move science in new directions seeks challenging opportunities beyond the bench.
Jason C. Poole has 17 years of experience as a molecular biologist developing novel molecular and genetic assays. He has a PhD in molecular genetics and most recently worked at EMD Millipore developing qPCR and next generation sequencing assays that were commercialized. He is seeking a senior scientist or project leader position and has strong skills in areas like qPCR, sequencing, cloning, and assay development.
This document contains the curriculum vitae of Kun Yang. It summarizes his education, research experience, publications, conference presentations, honors and awards. Yang received a B.S. in Biotechnology from Beijing Normal University in 2006, and is currently pursuing a Ph.D. in Pathobiology at Brown University, with a focus on epigenetic regulation of bone development and osteoarthritis. His research has identified miR-365 and the Ihh signaling pathway as critical regulators of bone mineral density and osteoarthritis.
Alex Michael Ward is a virologist and cell biologist seeking a research position in biotech. He has 14 years of experience studying virus-host interactions and identifying therapeutic targets using genetic, proteomic, and cell-based approaches. He is a highly collaborative scientist who has independently managed a research team and obtained external funding. His work has resulted in numerous publications, presentations, and the development of novel assays.
Vani Hariharan has extensive experience in cellular biology, neurobiology, and developmental biology. She received her MS in Cellular Biology from the University of Georgia in 2013 and her BE in Biotechnology from Visvesvaraya Technological University in 2009. Her research has focused on studying Duchenne Muscular Dystrophy using zebrafish models and characterizing drug resistance in malaria parasites. She has worked as a research assistant at the University of Virginia and University of Georgia.
Kent E. Williams has extensive experience in neuroscience research. He holds an M.Sc. in Biology from Indiana State University and has completed coursework toward a Ph.D. in Neuroscience from Ohio State University. His research has focused on extracellular matrix proteins and their implications for angiogenesis and spinal cord injury. He has worked as an adjunct instructor and laboratory director and currently teaches at Vincennes University.
Kelvin Yaprianto is a biochemist from Indonesia who received his Bachelor of Science with Honours degree from the Walter and Eliza Hall Institute of Medical Research in Australia in 2013. He has extensive research experience investigating the roles of NF-虜B family transcription factors in promoting tumor cell survival and metastasis. Currently he works as a research assistant in stem cell and cancer research at PT. Kalbe Farma Tbk. in Jakarta.
Dhruv Patel is a research associate with expertise in molecular and cellular biology techniques including cloning, PCR, transfection and cell-based assays. He has work experience in pharmaceutical companies conducting discovery research to identify new drug targets. His education includes a M.S. in biological sciences and B.S. in pharmaceutical sciences. He is highly skilled in laboratory techniques and able to work independently or collaborate with others.
Genomics is the study of genomes through gene sequencing and comparisons within and across species. The Human Genome Project sequenced all human DNA. Technology allows study of genes and proteins through databases, microarrays, and proteomics. Genetic screening tests DNA to detect genetic disorders and cancer risk, while gene therapy aims to replace faulty genes as a treatment.
Assn. for molecular pathology vs. mtriad genetics case studyAltacit Global
油
This document summarizes a case study on the lawsuit between the Association for Molecular Pathology and Myriad Genetics regarding patents on the BRCA1 and BRCA2 genes. Myriad's scientists discovered the genes linked to breast cancer in 1994 and were granted patents. However, a lawsuit challenged the patents, arguing that genes cannot be patented. While a district court invalidated Myriad's patents, an appeals court upheld them. Ultimately, the US Supreme Court ruled that isolated DNA is not patentable subject matter, invalidating Myriad's patents.
Managing Health and Disease Using Omics and Big DataLaura Berry
油
Presented at the NGS Tech and Applications Congress: USA. To find out more, visit:
www.global-engage.com
Michael Snyder is a Professor, Chair of Genetics and Director of the Stanford Center for Genomics and Personalized Medicine at Stanford University. In this presentation Michael discusses using omics and big data to predict disease risk and catch early disease onset.
Geron's halted clinical trial using embryonic stem cell derivatives to treat spinal cord injury highlighted important lessons. Two key prerequisites for successful translation of pluripotent stem cell therapies are (1) reproducible growth and differentiation of stem cells in good manufacturing practice conditions to ensure a controlled cell source, and (2) extensive safety studies in animal models to determine adverse effects like teratoma formation and improve the treatment procedure. The intention to be first can disadvantage a trial by rushing critical development steps.
The document discusses the integration of diverse large-scale datasets to build comprehensive protein-protein interaction networks. It describes challenges with data from different sources having different identifiers, evidence types and quality. It also discusses methods used by STRING and other databases to combine data from curated databases, literature mining, primary datasets and transfer of interactions based on orthology. Examples are given of cell cycle studies in yeast that have analyzed periodically expressed genes and protein interactions.
This document provides a summary of Michael L. Avery's education and professional experience. He holds a BS and BGS in Cell Biology and Microbiology from the University of Kansas, and an MA in Microbiology. His experience includes over 13 years in analytical sciences and process development at Amgen, analytical chemistry research at Sigma-Aldrich Biosciences, and various roles supporting drug development and preclinical studies at 3M Pharmaceuticals and Quintiles. He has extensive experience in analytical techniques such as HPLC, CE, LC/MS, and related methods for characterizing proteins and small molecules.
A normal cell can be transformed into a cancerous cell. Discuss the therapeutic strategies that are employed to target the cellular transformation process for cancer prevention and treatment.
This curriculum vitae summarizes the educational and professional experience of Dr. Wen-Hai Chou. He received his PhD from the University of Texas Health Science Center in 2000 and is currently an Assistant Professor at Kent State University. His research focuses on the roles of Protein Kinase C and Lipocalin-2 in stroke. He has over 10 peer-reviewed publications in high impact journals such as the Journal of Neuroscience and Journal of Biological Chemistry.
This document provides a summary of Jack Ryan Reifert's education, experience, publications, and research skills. Reifert holds a Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB and a B.S. in Pharmacological Chemistry from UCSD. He has postdoctoral research experience at UCSB studying bacterial peptide display for ovarian cancer detection and inhibition. Reifert has over 10 years of experience in neuroscience research and industrial research, and he has authored several publications in peer-reviewed journals.
Sijin Wu has a Ph.D. in Biochemical Engineering and extensive experience in computational biology and computer-aided drug design. His research focuses on protein modeling, molecular dynamics simulation, and virtual screening. He has authored or co-authored over 15 publications and developed databases on proteins with targetable cysteines and cancer stem cell therapeutic targets. Wu seeks postdoctoral opportunities to further his work in these fields.
Jack Ryan Reifert is seeking a post-doctoral position in molecular mechanisms of age-related human diseases. He received his Ph.D. in Molecular, Cellular, and Developmental Biology from UCSB, where his dissertation research investigated amyloid beta-induced neurodegeneration and the role of tau phosphorylation and cleavage. He has research experience in academia and industry, including publications, and is currently investigating tau fragmentation and amyloid beta signaling in neurodegeneration.
This resume summarizes the experience and qualifications of Karen Shiner, a biochemist with expertise in G protein-coupled receptor signaling and voltage-gated calcium channels. As a postdoctoral fellow, she discovered that epilepsy and ataxia in a mouse model were not caused by perturbations in P-type calcium channels as previously thought. During graduate school, she explained incongruous rates in a G protein signaling pathway and developed new assays. She has strong skills in protein biochemistry, receptor-ligand interactions, enzymology, subcloning, and cell culture, and experience training and supervising others.
This document provides a summary of qualifications and work experience for Jenne M. Westberry, PhD. She has over 10 years of postgraduate laboratory experience in neuroscience, aging, women's health and epigenetics. Her experience includes managing laboratories, writing and overseeing NIH grants, scientific writing and editing, course instruction, and conducting experiments using techniques such as immunohistochemistry and methylation-specific PCR. She has a strong publication record and has presented her research findings at numerous scientific conferences.
This document is a resume for Jonathon N. Winnay, Ph.D. that summarizes his professional experience and qualifications. It describes him as an accomplished scientist with an established record of innovative research in areas like diabetes, metabolism, and obesity. He has over 15 years of experience performing mechanistic studies using in vitro and in vivo models at Joslin Diabetes Center and Harvard Medical School. The resume lists his extensive laboratory skills and experience managing research projects and students.
Hao Liu has over 15 years of experience in drug discovery research. He has developed biochemical and cell-based assays to screen for oncology and metabolic disease targets. He is skilled in developing and optimizing high throughput screening assays, cell signaling studies, and molecular biology techniques. Liu has authored several publications and presented at conferences.
Lorraine Suhadolnik is a research scientist with extensive experience in drug discovery. She has a diverse skill set including molecular biology, protein biochemistry, assay development, screening, and tissue culture. She has worked in pharmaceutical research for over 20 years, developing assays and furthering projects independently and as part of a team. Her expertise lies in areas such as GPCR assays, screening, molecular biology techniques, and protein work. She is an excellent communicator and team member.
Next Generation Sequencing and its Applications in Medical Research - Frances...Sri Ambati
油
The so-called next-generation sequencing (NGS) technologies allows us, in a short time and in parallel, to sequence massive amounts of DNA, overcoming the limitations of the original Sanger sequencing methods used to sequence the first human genome. NGS technologies have had an enormous impact on biomedical research within a short time frame. This talk will give an overview of these applications with specific examples from Mendelian genomics and cancer research. #h2ony
Jack Reifert has over 15 years of experience in biomedical research. He received his Ph.D. in Molecular, Cellular, and Developmental Biology from UC Santa Barbara and has worked in both academic and industry research settings. Currently he is a scientist at Serimmune Inc. where he utilizes techniques like peptide display screening and deep sequencing to identify biomarkers and therapeutic candidates for autoimmune diseases.
This curriculum vitae summarizes the career and qualifications of John Patrick Alao. It lists his current position as a Principal Research Scientist at Gothenburg University since 2010. It also outlines his extensive experience, including previous roles as a senior postdoctoral fellow and EMBO postdoctoral fellow at Gothenburg University from 2009-2007. The CV details his education, achieving a PhD from Imperial College London in 2004 and a BSc in Biochemistry with Honors from the University of East London in 1999. It lists over 25 peer-reviewed publications and provides names for references.
MinHee K. Ko has extensive research experience in ocular diseases including uveitis, retinal ischemia, glaucoma, and neurodegenerative diseases. She has a Ph.D. in pathobiology from USC and has held postdoctoral positions focused on immune-based therapies for neurodegenerative disorders and ocular pathology. Her research experience includes developing novel therapeutics for glaucoma using animal models and examining innate immune-mediated photoreceptor cell death in uveitis models.
Xuhui Liu is an experienced physician-scientist specializing in biomedical research. He has over 20 years of experience conducting clinical and preclinical research focused on musculoskeletal and neurological diseases. Currently, he is an Associate Professor at UCSF leading multiple research programs investigating bone regeneration, rotator cuff injuries, and neuro-musculoskeletal trauma. He has published extensively in peer-reviewed journals and serves as a reviewer for several orthopedic research publications.
Lindsay Jordan has over 15 years of experience in the pharmaceutical industry, specializing in immunology techniques including cell culture, molecular biology, and ELISA development. She has worked at Biothera Pharmaceuticals since 2007 where she developed and validated potency assays, authored SOPs, and supported clinical trials. Prior to this, she held positions at 3M Pharmaceuticals and ViroMED Laboratories, optimizing assays and discovering drug mechanisms of action. Jordan has a Bachelor's degree in Biology and is proficient in laboratory techniques and data analysis software. She has authored multiple publications and presentations on topics including beta-glucan immunology and cancer immunotherapy.
This document summarizes the qualifications and experience of Shumei Ren, a biomedical research investigator specializing in oncological diseases. Ren has over 15 years of experience in molecular biology, pharmacology, and various techniques including flow cytometry, in vitro assays, and high throughput methods. Ren's professional experience includes positions at Thomas Jefferson University, Albany Medical College, and Hokkaido University investigating topics such as gastric cancer, prostate cancer, fibrosis, and hematopoietic malignancies.
Xuhui Liu is an experienced physician-scientist specializing in biomedical research. He has over 20 years of experience conducting clinical and preclinical research focused on musculoskeletal and neurological diseases. Currently, he is an Associate Professor at UCSF leading research programs in bone health, rotator cuff injuries, and neuro-musculoskeletal trauma. He has published over 30 peer-reviewed papers and is an active reviewer for several academic journals.
Romain Banchereau is a computational biologist and translational immunologist focused on analyzing immune cell populations and transcriptional profiles from human disease cohorts. He has expertise in genomics analysis of blood and immune cells from infectious and autoimmune disease patients. Through bioinformatics analysis, he identifies biomarkers for disease diagnosis, prognosis, and response to treatment. He currently works as a research associate applying these skills to study lupus, juvenile arthritis, and complications during pregnancy with SLE.
Victor Ozols has over 20 years of experience in laboratory research focusing on diseases such as cancer, Parkinson's, cystic fibrosis, Alzheimer's, and multiple sclerosis. He is looking for a new position where he can utilize his management, education, and research skills and continue enhancing these abilities. He has managed laboratories, identified potential drug compounds, and published numerous papers in peer-reviewed journals.
This document summarizes the credentials and experience of Dun Li, Ph.D., a cancer biologist and research scientist. Li has over 10 years of experience in molecular biology, cancer research, and drug development. He is currently a postdoctoral fellow at Boston University developing transgenic zebrafish models of breast cancer, leukemia, and neuroblastoma. Previously, Li received his Ph.D. from Stony Brook University studying mutant p53 and cancer drug resistance. He has authored 7 peer-reviewed publications and received NIH training grants. Li is seeking a position where he can apply his expertise in cancer biology, molecular biology techniques, and animal model development.
This document provides a summary of Aaron M Bender's background and experience. It includes his contact information, educational background which includes a PhD in Molecular Biology from the University of Wyoming, and extensive research experience including positions at ArcherDX, the University of Kansas Molecular Probes Core Laboratory, the University of Kansas, and the Mayo Clinic where he conducted research in areas such as cancer genetics, chemical biology, next generation sequencing, and the use of model organisms like C. elegans. He has over 15 publications in peer-reviewed journals.
1. Jane Yang Resume
1
Jane Yang, PhD
261 La Cuesta Dr., Portola Valley, CA 94028 janeyangzte@gmail.com (206) 218-3796
http://www.linkedin.com/pub/jane-yang-phd/5/104/7a5
Scientist who thrives in a team-oriented environment and employs critical thinking and extensive hands-
on experience to advance challenging projects with competing priorities. Experimentalist, a proven
ability to rapidly devise practical tests of hypotheses using multidisciplinary approaches. Dot connector,
seeking out expertise and initiating collaborations in diverse fields. Good listener, mentored and trained
research associates on independent projects.
Core Competencies:
Transcriptional and epigenetic regulation
Cancer biology
Cell differentiation and development
Early discovery and mechanisms of action
Chemical and genetic modulation of cell fate and behavior
Publications and awarded competitive research grants.
Technical Skills:
Molecular and biochemical methodologies
Proteomic, genomic, and epigenetic approaches
Mammalian and bacterial protein expression and purification
Cell- and enzyme-based assays
Multicolor flow cytometry and microscopy
Tissue cultures, primary cells, mouse embryo work
PROFESSIONAL EXPERIENCE
Visiting Scientist 2/2015 9/2016
Early Discovery Biochemistry, Genentech, South San Francisco, CA
Discovered new mechanisms of action of two small molecule inhibitors in order to advance early stage
research and discovery programs in therapeutic targeting of bromodomains (manuscript in preparation).
Identified erythroleukemia cells and primary erythroid precursors as model systems, leading to
two unique cell-based functional characterizations of the small molecules.
Defined drug dosage range and temporal window of activity through identifying and analyzing
induction of apoptosis and expression of target genes and cell-fate surface markers.
Designed, expressed, and purified one transcription factor heterodimer; devised in vitro and in
vivo acetylation assays for inter- and intra-team collaborations aimed at epigenetic inhibitors.
Research Scientist 3/2008 2/2015
Stanford University, Stanford, CA
Designed and applied genetic and chemical approaches to modulate cell fate and cell behavior in
response to genotoxic stress, somatic reprogramming to pluripotency, and Wnt signaling.
Project I: A multidisciplinary collaboration in discovering a previously unknown mechanistic link
between p53 and muscle differentiation in response to genotoxic stress, clarified a discrepancy in
2. Jane Yang Resume
2
understanding p53 as a stress sensor in regulating muscle cell fate, and confirming existence of a
differentiation checkpoint control (Yang et al., 2015, a featured article with an editorial highlight).
Designed and executed five independent cell-based assays and collected complex data sets to
study impact of genotoxic stress on cell fate and behavior during muscle differentiation.
Led three technical innovations:
Quantitatively tuning p53 protein levels to control cell fate output;
Simultaneous characterization of cell cycle and a nuclear factor by flow cytometry;
Visualization and quantification of post-mitotic nuclear integrity under genotoxic stress.
Discovered one novel enhancer bound by stress-sensing p53 and active histone markers.
Supported the PI in grant writing and preparation of manuscripts and guided research associates
in experimental design and data interpretation in a chemical engineering research environment.
Project II: Identified protein complexes of activation-induced cytidine deaminase (AID); Developed a
plasmid-based methylation-specific PCR and bisulfite sequencing of promoters of pluripotent genes.
Project III: Quantified cell polarity and migration of primary myoblasts in a chemotactic Wnt gradient.
Postdoctoral Research (NIH/NCI F32 National Research Service Award) 10/2003 - 3/2008
Fred Hutchinson Cancer Research Center, Seattle, WA
Applied large-scale genomic and proteomic datasets to identify and validate oncogenic factors,
discovered a novel mechanism of programming human rhabdomyosarcoma cells to terminal
differentiation; Opened new avenues for biomarker identification and design of differentiation therapy
(Yang et al., 2009) (Reviewed by F1000).
Staff Scientist Gene Switch Project 7/2001 - 9/2003
Maxygen Inc., Redwood City, CA
Evolved Aspergillus nidulans transcriptional factor AlcR by constructing site-directed degenerate
libraries and family-shuffled DNA libraries based on fragmentation and homology-dependent
reassembly of orthologues; Exceeded project goal by improving AlcR transactivation by 15 fold.
Doctoral Research (NIH Biotechnology Training Grant Fellowship) 9/1996 - 6/2001
University of California at Davis, Davis, CA
Interrogated transcriptional regulation by thyroid hormone receptors (Yang et al., 2001 and 1999).
EDUCATION
Ph.D. Microbiology, University of California at Davis, CA. 2001
M.S. Plant Virology, University of Minnesota at Twin Cities, MN. 1995
B.S. Plant Pathology, China Agricultural University, P. R. China. 1992
HONORS AND AWARDS
NIH/NCI F32 Ruth L. Kirschstein National Research Service Award (NRSA) (2006 - 2009)
FHCRC/Amgen Interdisciplinary Training Grant (2005 - 2006)
Fred Hutchinson Cancer Research Center Travel Grant (2006) and Course Award (2005-2006)
NIH/Amgen Biotechnology Training Grant Fellowship, UC Davis (1998 - 2001)
Excellent Undergraduate Scholarships at CAU, Beijing, China (1989 - 1992)
3. Jane Yang Resume
3
PUBLICATIONS
Yang, Z., Kenzelmann Broz, D., Noderer, W. L., Ferreira, J. P., Overton, K. W., Spencer, S. L.,
Meyer, T., Tapscott, S. J., Attardi, L. D., and Wang, C. L. (2015) p53 suppresses muscle
differentiation at myogenin step. Cell Death & Differentiation 22: 560-573.
Featured article with an editorial Muscle gets stressed? p53 represses and protects.
Yang, Z., MacQuarrie, K., Analau, E., Tyler, A., Dilworth, F.J., Cao, Y., Diede, S., and Tapscott, S.
J. (2009) MyoD and E-protein heterodimers switch rhabdomyosarcoma cells from an arrested
myoblast phase to a differentiated state. Genes & Development 23: 694-707 (Reviewed by Faculty
1000).
Olguin H. C., Yang, Z., Tapscott, S. J., and Olwin, B. B. (2007) Reciprocal inhibition between Pax7
and MRFs modulates myogenic cell fate determination. Journal of Cell Biology 177(5): 769-779.
Yang, Z., Nicolaisen, M., Olszewski, N. E., and Lockhart, B. E. L. (2005) Sequencing, improved
detection, and a novel form of Kalancho谷 top-spoting virus. Plant Disease 89 (3): 298-302.
Hong, S.-H., Yang, Z., and Privalsky, M. L. (2001) Arsenic trioxide is a potent inhibitor of the
interaction of SMRT corepressor with its transcription factor partners, including the PML-RAR留
oncoprotein found in human acute promyelocytic leukemia. Molecular and Cellular Biology 21(21):
7172-7182.
Yang, Z. and Privalsky, M. L. (2001) Isoform-specific transcriptional regulation by thyroid hormone
receptors: hormone-independent activation operates through a steroid receptor-mode of coactivator
interaction. Molecular Endocrinology 15 (7): 1170-1185.
Yang, Z., Hong, S.-H., and Privalsky, M. L. (1999) Transcriptional anti-repression: Thyroid hormone
receptor beta-2 recruits SMRT corepressor but interferes with subsequent assembly of a functional
corepressor complex. Journal of Biological Chemistry 274 (52): 37131-37138.